论文部分内容阅读
目的观察特拉唑嗪联合爱普列特治疗高血压病患者良性前列腺增生症(BPH)的临床疗效与安全性。方法入选伴有高血压病的BPH患者83例,受试者均口服盐酸特拉唑嗪2mg,每晚1次,爱普列特片5mg,bid,疗程4月。入选患者同时按中国高血压防治指南进行规则的降压治疗。采用国际前列腺症状评分(IPSS)、生活质量评分(QOL)、残余尿量(Ru)、最大尿流率(Qmax)、前列腺体积(PV)和前列腺特异抗原(PSA)等指标评价其临床疗效。结果与治疗前比较,治疗4月后,入选患者的IPSS、QOL、Ru、Qmax、PV和PSA均得到显著的改善(P<0.05)。特拉唑嗪联合爱普列特治疗BPH的总有效率为89.2%。治疗过程中患者的血压水平控制良好,未观察到明显的不良反应。结论特拉唑嗪联合爱普列特治疗高血压病患者良性前列腺增生症具有较好的疗效与安全性。
Objective To observe the clinical efficacy and safety of terazosin combined with epristeride in the treatment of benign prostatic hyperplasia (BPH) in hypertensive patients. Methods Eighty-three BPH patients with hypertension were enrolled in this study. All the patients were given oral terazosin hydrochloride 2mg once a night, and epristeride tablet 5mg bid for four months. Selected patients at the same time according to Chinese guidelines for the prevention and treatment of hypertension antihypertensive treatment. The clinical efficacy was evaluated by IPSS, QOL, Ru, Qmax, Prostate volume (PV) and prostate specific antigen (PSA). Results Compared with those before treatment, IPSS, QOL, Ru, Qmax, PV and PSA were significantly improved (P <0.05) after 4 months of treatment. The total effective rate of terazosin and eplerenol in the treatment of BPH was 89.2%. The patient’s blood pressure was well controlled during treatment, with no apparent adverse reactions observed. Conclusion Terazosin combined with Epristeride in patients with hypertensive benign prostatic hyperplasia has good efficacy and safety.